natgillin/translations-raw huggingface dataset:
Binocrit 10,000 IU/1 ml solution for injection in a pre-filled syringe Each syringe contains 1 ml of solution for injection.
Binocrit 10.000 i.e./1 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Ena napolnjena injekcijska brizga vsebuje 1 ml raztopine za injiciranje.
Binocrit 10,000 IU/1 ml solution for injection in a pre-filled syringe Epoetin alfa
Binocrit 10.000 i.e./1 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Epoetin alfa
Binocrit 10,000 IU/1 ml solution for injection in a pre-filled syringe EU/1/07/410/015
Binocrit 10.000 i.e./1 ml raztopina za injiciranje v napolnjeni injekcijski brizgi EU/1/07/410/015
Binocrit 2,000 IU/1 ml
Binocrit 2.000 i.e./1 ml
Binocrit 2,000 IU/1 ml injection
Binocrit 2.000 i.e./1 ml injekcija
Binocrit 2,000 IU/1 ml solution for injection in a pre-filled syringe
Binocrit 2.000 i.e./1 ml raztopina za injiciranje v napolnjeni injekcijski brizgi
Binocrit 2,000 IU/1 ml solution for injection in a pre-filled syringe Each syringe contains 1 ml of solution for injection.
Binocrit 2.000 i.e./1 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Ena napolnjena injekcijska brizga vsebuje 1 ml raztopine za injiciranje.
Binocrit 2,000 IU/1 ml solution for injection in a pre-filled syringe Epoetin alfa
Binocrit 2.000 i.e./1 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Epoetin alfa
Binocrit 2,000 IU/1 ml solution for injection in a pre-filled syringe EU/1/07/410/003
Binocrit 2.000 i.e./1 ml raztopina za injiciranje v napolnjeni injekcijski brizgi EU/1/07/410/003
Binocrit 20,000 IU/0.5 ml
Binocrit 20.000 i.e./0,5 ml
Binocrit 20,000 IU/0.5 ml injection
Binocrit 20.000 i.e./0,5 ml injekcija
Binocrit 20,000 IU/0.5 ml solution for injection in a pre-filled syringe
Binocrit 20.000 i.e./0,5 ml raztopina za injiciranje v napolnjeni injekcijski brizgi
Binocrit 20,000 IU/0.5 ml solution for injection in a pre-filled syringe Each syringe contains 0.5 ml of solution for injection.
Binocrit 20.000 i.e./0,5 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Ena napolnjena injekcijska brizga vsebuje 0,5 ml raztopine za injiciranje.
Binocrit 20,000 IU/0.5 ml solution for injection in a pre-filled syringe Epoetin alfa
Binocrit 20.000 i.e./0,5 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Epoetin alfa
Binocrit 20,000 IU/0.5 ml solution for injection in a pre-filled syringe EU/1/07/410/021
Binocrit 20.000 i.e./0,5 ml raztopina za injiciranje v napolnjeni injekcijski brizgi EU/1/07/410/021
Binocrit 3,000 IU/0.3 ml
Binocrit 3.000 i.e./0,3 ml
Binocrit 3,000 IU/0.3 ml injection
Binocrit 3.000 i.e./0,3 ml injekcija
Binocrit 3,000 IU/0.3 ml solution for injection in a pre-filled syringe
Binocrit 3.000 i.e./0,3 ml raztopina za injiciranje v napolnjeni injekcijski brizgi
Binocrit 3,000 IU/0.3 ml solution for injection in a pre-filled syringe Each syringe contains 0.3 ml of solution for injection.
Binocrit 3.000 i.e./0,3 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Ena napolnjena injekcijska brizga vsebuje 0,3 ml raztopine za injiciranje.
Binocrit 3,000 IU/0.3 ml solution for injection in a pre-filled syringe Epoetin alfa
Binocrit 3.000 i.e./0,3 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Epoetin alfa
Binocrit 3,000 IU/0.3 ml solution for injection in a pre-filled syringe EU/1/07/410/005
Binocrit 3.000 i.e./0,3 ml raztopina za injiciranje v napolnjeni injekcijski brizgi EU/1/07/410/005
Binocrit 30,000 IU/0.75 ml
Binocrit 30.000 i.e./0,75 ml
Binocrit 30,000 IU/0.75 ml injection
Binocrit 30.000 i.e./0,75 ml injekcija
Binocrit 30,000 IU/0.75 ml solution for injection in a pre-filled syringe
Binocrit 30.000 i.e./0,75 ml raztopina za injiciranje v napolnjeni injekcijski brizgi
Binocrit 30,000 IU/0.75 ml solution for injection in a pre-filled syringe Each syringe contains 0.75 ml of solution for injection.
Binocrit 30.000 i.e./0,75 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Ena napolnjena injekcijska brizga vsebuje 0,75 ml raztopine za injiciranje.
Binocrit 30,000 IU/0.75 ml solution for injection in a pre-filled syringe Epoetin alfa
Binocrit 30.000 i.e./0,75 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Epoetin alfa
Binocrit 30,000 IU/0.75 ml solution for injection in a pre-filled syringe EU/1/07/410/023
Binocrit 30.000 i.e./0,75 ml raztopina za injiciranje v napolnjeni injekcijski brizgi EU/1/07/410/023
Binocrit 4,000 IU/0.4 ml
Binocrit 4.000 i.e./0,4 ml
Binocrit 4,000 IU/0.4 ml injection
Binocrit 4.000 i.e./0,4 ml injekcija
Binocrit 4,000 IU/0.4 ml solution for injection in a pre-filled syringe
Binocrit 4.000 i.e./0,4 ml raztopina za injiciranje v napolnjeni injekcijski brizgi
Binocrit 4,000 IU/0.4 ml solution for injection in a pre-filled syringe Each syringe contains 0.4 ml of solution for injection.
Binocrit 4.000 i.e./0,4 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Ena napolnjena injekcijska brizga vsebuje 0,4 ml raztopine za injiciranje.
Binocrit 4,000 IU/0.4 ml solution for injection in a pre-filled syringe Epoetin alfa
Binocrit 4.000 i.e./0,4 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Epoetin alfa
Binocrit 4,000 IU/0.4 ml solution for injection in a pre-filled syringe EU/1/07/410/007
Binocrit 4.000 i.e./0,4 ml raztopina za injiciranje v napolnjeni injekcijski brizgi EU/1/07/410/007
Binocrit 40,000 IU/1 ml
Binocrit 40.000 i.e./1 ml
Binocrit 40,000 IU/1 ml injection
Binocrit 40.000 i.e./1 ml injekcija
Binocrit 40,000 IU/1 ml solution for injection in a pre-filled syringe
Binocrit 40.000 i.e./1 ml raztopina za injiciranje v napolnjeni injekcijski brizgi
Binocrit 40,000 IU/1 ml solution for injection in a pre-filled syringe Each syringe contains 1 ml of solution for injection.
Binocrit 40.000 i.e./1 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Ena napolnjena injekcijska brizga vsebuje 1 ml raztopine za injiciranje.
Binocrit 40,000 IU/1 ml solution for injection in a pre-filled syringe Epoetin alfa
Binocrit 40.000 i.e./1 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Epoetin alfa
Binocrit 40,000 IU/1 ml solution for injection in a pre-filled syringe EU/1/07/410/025
Binocrit 40.000 i.e./1 ml raztopina za injiciranje v napolnjeni injekcijski brizgi EU/1/07/410/025
Binocrit 5,000 IU/0.5 ml
Binocrit 5.000 i.e./0,5 ml
Binocrit 5,000 IU/0.5 ml injection
Binocrit 5.000 i.e./0,5 ml injekcija
Binocrit 5,000 IU/0.5 ml solution for injection in a pre-filled syringe
Binocrit 5.000 i.e./0,5 ml raztopina za injiciranje v napolnjeni injekcijski brizgi
Binocrit 5,000 IU/0.5 ml solution for injection in a pre-filled syringe Each syringe contains 0.5 ml of solution for injection.
Binocrit 5.000 i.e./0,5 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Ena napolnjena injekcijska brizga vsebuje 0,5 ml raztopine za injiciranje.
Binocrit 5,000 IU/0.5 ml solution for injection in a pre-filled syringe Epoetin alfa
Binocrit 5.000 i.e./0,5 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Epoetin alfa
Binocrit 5,000 IU/0.5 ml solution for injection in a pre-filled syringe EU/1/07/410/009
Binocrit 5.000 i.e./0,5 ml raztopina za injiciranje v napolnjeni injekcijski brizgi EU/1/07/410/009
Binocrit 6,000 IU/0.6 ml
Binocrit 6.000 i.e./0,6 ml
Binocrit 6,000 IU/0.6 ml injection
Binocrit 6.000 i.e./0,6 ml injekcija
Binocrit 6,000 IU/0.6 ml solution for injection in a pre-filled syringe
Binocrit 6.000 i.e./0,6 ml raztopina za injiciranje v napolnjeni injekcijski brizgi
Binocrit 6,000 IU/0.6 ml solution for injection in a pre-filled syringe Each syringe contains 0.6 ml of solution for injection.
Binocrit 6.000 i.e./0,6 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Ena napolnjena injekcijska brizga vsebuje 0,6 ml raztopine za injiciranje.
Binocrit 6,000 IU/0.6 ml solution for injection in a pre-filled syringe Epoetin alfa
Binocrit 6.000 i.e./0,6 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Epoetin alfa
Binocrit 6,000 IU/0.6 ml solution for injection in a pre-filled syringe EU/1/07/410/011
Binocrit 6.000 i.e./0,6 ml raztopina za injiciranje v napolnjeni injekcijski brizgi EU/1/07/410/011
Binocrit 7,000 IU/0.7 ml
Binocrit 7.000 i.e./0,7 ml
Binocrit 7,000 IU/0.7 ml injection
Binocrit 7.000 i.e./0,7 ml injekcija
Binocrit 7,000 IU/0.7 ml solution for injection in a pre-filled syringe
Binocrit 7.000 i.e./0,7 ml raztopina za injiciranje v napolnjeni injekcijski brizgi
Binocrit 7,000 IU/0.7 ml solution for injection in a pre-filled syringe Each syringe contains 0.7 ml of solution for injection.
Binocrit 7.000 i.e./0,7 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Ena napolnjena injekcijska brizga vsebuje 0,7 ml raztopine za injiciranje.
Binocrit 7,000 IU/0.7 ml solution for injection in a pre-filled syringe Epoetin alfa
Binocrit 7.000 i.e./0,7 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Epoetin alfa
Binocrit 7,000 IU/0.7 ml solution for injection in a pre-filled syringe EU/1/07/410/017
Binocrit 7.000 i.e./0,7 ml raztopina za injiciranje v napolnjeni injekcijski brizgi EU/1/07/410/017
Binocrit 8,000 IU/0.8 ml
Binocrit 8.000 i.e./0,8 ml
Binocrit 8,000 IU/0.8 ml injection
Binocrit 8.000 i.e./0,8 ml injekcija
Binocrit 8,000 IU/0.8 ml solution for injection in a pre-filled syringe
Binocrit 8.000 i.e./0,8 ml raztopina za injiciranje v napolnjeni injekcijski brizgi
Binocrit 8,000 IU/0.8 ml solution for injection in a pre-filled syringe Each syringe contains 0.8 ml of solution for injection.
Binocrit 8.000 i.e./0,8 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Ena napolnjena injekcijska brizga vsebuje 0,8 ml raztopine za injiciranje.
Binocrit 8,000 IU/0.8 ml solution for injection in a pre-filled syringe Epoetin alfa
Binocrit 8.000 i.e./0,8 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Epoetin alfa
Binocrit 8,000 IU/0.8 ml solution for injection in a pre-filled syringe EU/1/07/410/013
Binocrit 8.000 i.e./0,8 ml raztopina za injiciranje v napolnjeni injekcijski brizgi EU/1/07/410/013
Binocrit 9,000 IU/0.9 ml
Binocrit 9.000 i.e./0,9 ml
Binocrit 9,000 IU/0.9 ml injection
Binocrit 9.000 i.e./0,9 ml injekcija
Binocrit 9,000 IU/0.9 ml solution for injection in a pre-filled syringe
Binocrit 9.000 i.e./0,9 ml raztopina za injiciranje v napolnjeni injekcijski brizgi
Binocrit 9,000 IU/0.9 ml solution for injection in a pre-filled syringe Each syringe contains 0.9 ml of solution for injection.
Binocrit 9.000 i.e./0,9 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Ena napolnjena injekcijska brizga vsebuje 0,9 ml raztopine za injiciranje.
Binocrit 9,000 IU/0.9 ml solution for injection in a pre-filled syringe Epoetin alfa
Binocrit 9.000 i.e./0,9 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Epoetin alfa
Binocrit 9,000 IU/0.9 ml solution for injection in a pre-filled syringe EU/1/07/410/019
Binocrit 9.000 i.e./0,9 ml raztopina za injiciranje v napolnjeni injekcijski brizgi EU/1/07/410/019
Binocrit contains less than 1 mmol sodium (23 mg) per dose i.e. essentially “sodium free”.
Zdravilo Binocrit vsebuje manj kot 1 mmol (23 mg) natrija na odmerek, kar v bistvu pomeni „brez natrija“.
Binocrit contains the active substance epoetin alfa, a protein that stimulates the bone marrow to produce more red blood cells which carry haemoglobin (a substance that transports oxygen).
Zdravilo Binocrit vsebuje zdravilno učinkovino epoetin alfa, beljakovino, ki spodbuja kostni mozeg k tvorbi rdečih krvnih celic, ki prenašajo hemoglobin (snov, ki prenaša kisik).
Binocrit does not normally react with other medicines but please tell your doctor if you are using, have recently used or might use any other medicines, including medicines obtained without a prescription.
Zdravilo Binocrit običajno ne reagira z drugimi zdravili, vendar obvestite svojega zdravnika, če uporabljate (ali ste pred kratkim uporabljali) katero koli zdravilo, tudi če ste ga dobili brez recepta.
Binocrit has no or negligible influence on the ability to drive and use machines.
Zdravilo Binocrit nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
Binocrit is a solution for injection.
Zdravilo Binocrit je raztopina za injiciranje.
Binocrit is a ‘biosimilar’ medicine.
Zdravilo Binocrit je podobno biološko zdravilo.
Binocrit is given as an injection into a vein or as an injection under the skin, depending on the condition for which the patient is being treated.
Zdravilo Binocrit se daje z injiciranjem v veno ali podkožje, odvisno od bolezenskega stanja bolnika, ki se zdravi.
Binocrit is given by injection into a vein immediately after you have donated blood for 3 weeks before your surgery.
Zdravilo Binocrit se injicira v veno takoj po tem, ko darujete kri, 3 tedne pred kirurškim posegom.
Binocrit is given by injection under the skin each week for three weeks before surgery and on the day of surgery.
Zdravilo Binocrit se injicira pod kožo vsak teden tri tedne pred kirurškim posegom in na dan kirurškega posega.
Binocrit is given by injection under the skin.
Zdravilo Binocrit se daje v obliki injekcije pod kožo.
Binocrit is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (CRF):
Zdravilo Binocrit je indicirano za zdravljenje simptomatske anemije, povezane s kronično ledvično odpovedjo:
Binocrit is indicated in adults receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient’s general status (e.g. cardiovascular status, pre-existing anaemia at the start of chemotherapy) for the treatment of anaemia and reduction of transfusion requirements.
Zdravilo Binocrit je indicirano za zdravljenje odraslih, pri katerih s kemoterapijo zdravimo solidne tumorje, maligni limfom ali multipli mielom, in pri tveganju za transfuzijo, ki ga ocenimo glede na bolnikovo splošno zdravstveno stanje (npr. kardiovaskularni status, prisotnost anemije že na začetku zdravljenja s kemoterapijo) za zdravljenje anemije in zmanjšanje potrebe po transfuziji.
Binocrit is presented as a clear, colourless solution for injection in a pre-filled syringe.
Zdravilo Binocrit je bistra, brezbarvna raztopina za injiciranje v napolnjeni injekcijski brizgi.
Binocrit is used for the following:
Zdravilo Binocrit se uporablja v naslednjih primerih:
Binocrit may not be suitable for you.
ne morete jemati zdravil za redčenje krvi zdravilo Binocrit morda za vas ni primerno.
Binocrit should be administered in order to increase haemoglobin to not greater than 11 g/dl (6.8 mmol/l).
Zdravilo Binocrit se daje z namenom zvišati hemoglobin na raven do 11 g/dl (6,8 mmol/l).
Binocrit should be administered in order to increase haemoglobin to not greater than 12 g/dl (7.5 mmol/l).
Zdravilo Binocrit se daje z namenom zvišati hemoglobin na raven do 12 g/dl (7,5 mmol/l).
Binocrit should be administered to patients with anaemia (e.g. haemoglobin concentration ≤ 10 g/dl (6.2 mmol/l)).
Bolnikom z anemijo (npr. s koncentracijo hemoglobina ≤ 10 g/dl (6,2 mmol/l)) je treba zdravilo Binocrit dajati subkutano.
Binocrit should not be used and discarded
Zdravila Binocrit se ne sme uporabiti in ga je treba zavreči:
Binocrit should not be used:
Zdravila Binocrit ne uporabljajte:
Binocrit was as effective as Eprex/Erypo in increasing and maintaining red blood cell counts.
Zdravilo Binocrit je bilo pri zviševanju in vzdrževanju števila rdečih krvnih celic enako učinkovito kot zdravilo Eprex/Erypo.
Binocrit was studied to show that it is comparable to the reference medicine, Eprex/Erypo.
Zdravilo Binocrit so proučevali, da bi dokazali, ali je primerljivo z referenčnim zdravilom Eprex/Erypo.
Bio-Set System:
Bio-Set sistem:
Bioavailability (AUC and Cmax) is comparable for Adempas administered orally as a crushed tablet suspended in applesauce or in water compared to a whole tablet (see section 4.2).
Biološka uporabnost (AUC in Cmax) peroralno dane zdrobljene tablete zdravila Adempas, zmešane z jabolčno čežano ali vodo, je primerljiva z biološko uporabnostjo cele tablete (glejte poglavje 4.2).
Bioavailability (AUC and Cmax) was comparable for 20 mg rivaroxaban administered orally as a crushed tablet mixed in apple puree, or suspended in water and administered via a gastric tube followed by a liquid meal, compared to a whole tablet.
Biološka uporabnost (AUC in Cmax) 20 mg rivaroksabana, uporabljenega peroralno v obliki zdrobljene tablete pomešane z jabolčno čežano ali raztopljenega v vodi in danega po želodčni sondi pred tekočim obrokom, je bila primerljiva z biološko uporabnostjo cele tablete.
Bioavailability and absorption
Biološka uporabnost in absorpcija
Bioavailability and pharmacokinetics of ibandronic acid are similar in men and women.
Biološka uporabnost in farmakokinetika ibandronske kisline sta pri moških in ženskah podobni.
Bioavailability in SJIA patients has not been determined independently.
Pri bolnikih s SJIA niso posebej določali biološke uporabnosti kanakinumaba.
Bioavailability is approximately 93-100% based on recoveries of unmetabolised amifampridine and a major 3-N-acetylated amifampridine metabolite in urine.
Biološka uporabnost je približno 93 – 100%, na podlagi zaznanega nepresnovljenega zdravila in glavnega presnovka 3-N-acetiliranega amifampridina v urinu.
Bioavailability is reduced by about 90 % when ibandronic acid is administered with a standard breakfast in comparison with bioavailability seen in fasted subjects.
Pri sočasnem uživanju ibandronske kisline s standardnim zajtrkom se biološka uporabnost zmanjša za okoli 90 % v primerjavi z biološko uporabnostjo, ki so jo opazili pri teščih bolnikih.
Bioavailability of dolutegravir depends on meal content: low, moderate, and high fat meals increased dolutegravir AUC(0-) by 33%, 41%, and 66%, increased Cmax by 46%, 52%, and 67%, prolonged Tmax to 3, 4, and 5 hours from 2 hours under fasted conditions, respectively.
Biološka uporabnost dolutegravirja je odvisna od sestave obroka: malo masten, zmerno masten oziroma zelo masten obrok poveča AUC(0-) dolutegravirja za 33 %, 41 % oziroma 66 % ter poveča Cmax za 46 %, 52 % oziroma 67 %, Tmax pa podaljša na 3, 4 oziroma 5 ur (z 2 ur po uporabi na tešče).
Bioavailability of inhaled human insulin relative to subcutaneously administered fast-acting human insulin was comparable to those in younger adult subjects with type 2 diabetes.
Biološka uporabnost humanega insulina za inhaliranje glede na subkutano injicirani hitrodelujoči humani insulin je bila primerljiva s tisto pri mlajših odraslih bolnikih z diabetesom tipa 2.
Bioavailability was reduced by approximately 75% when Bondronat tablets were administered 2 hours after a standard meal.
Ko so tablete Bondronat dali 2 uri po standardnem obroku, se je biološka uporabnost zmanjšala za 75 %.
Bioavailability was reduced by approximately 75% when Iasibon tablets were administered 2 hours after a standard meal.
Ko so tablete Iasibon dali 2 uri po standardnem obroku, se je biološka uporabnost zmanjšala za 75 %.
Bioavailability was reduced by approximately 75% when ibandronic acid tablets were administered 2 hours after a standard meal.
Ko so ibandronsko kislino jemali 2 uri po standardnem obroku, je bila biološka uporabnost zmanjšana za približno 75 %.
Bioavailability was reduced by approximately 75% when ibandronic acid tablets were administered 2 hours after a standard meal.
Ko so tablete z ibandronsko kislino jemali dve uri po standardnem obroku, je bila biološka uporabnost zmanjšana za približno 75 %.
Bioavailability was shown to be approximately 100%, with maximum plasma concentrations attained approximately 4–12 hours post treatment, and with half-lives of spinosyn A and spinosyn D ranging between 5 days and 20 days in cats dosed at
Ugotovljeno je bilo, da je biološka razpoložljivost približno 100 %, največja plazemska koncentracija pa se je pojavila v 4–12 urah po zdravljenju.
Biochemical and metabolic laboratory test abnormalities
Nenormalni izvidi laboratorijskih biokemičnih preiskav in preiskav presnove
Biochemiestrasse 10 AT-6250 Kundl Austria
Biochemiestrasse 10 AT-6250 Kundl Avstrija
Biochemistry changes associated with kidney function including decreases in urine-specific gravity and pH and slight increases in blood urea nitrogen and sporadic increases in creatinine were present in both rat and dog after treatment of two weeks.
Biokemične spremembe, povezane z delovanjem ledvic, vključno z znižanjem specifične teže urina,in pH urina ter blagim povišanjem dušika sečnine v krvi in sporadičnim povišanjem kreatinina so bile po 2-tedenskem zdravljenju prisotne pri podganah in psih.
Biocodex, 7 Avenue Gallieni, 94250 Gentilly, France.
Biocodex, 7 Avenue Gallieni, 94250 Gentilly, Francija.
Biodex 150-001 Red Strips
Listič Biodex 150-001 Red Strips
Bioequivalence
Bioekvivalenca
Bioequivalence boundary 80%-125%
Meje bioekvivalence 80 %-125
Bioequivalence of Glubrava with co-administered pioglitazone and metformin has also been demonstrated (see section 5.2).
Dokazana je bila tudi bioekvivalenca zdravila Glubrava ob sočasnem dajanju s pioglitazonom in z metforminom (glejte poglavje 5.2).
Bioequivalence/Equivalence boundary 80-125%.
Meja bioekvivalence/ekvivalence 80–125 %.
Biogen (Denmark) Manufacturing ApS, Biogen Allé 1, DK-3400 Hillerød, Denmark.
Biogen (Denmark) Manufacturing ApS, Biogen Allé 1, DK-3400 Hillerød, Danska
Biogen Idec Limited Innovation House 70 Norden Road Maidenhead Berkshire
Biogen Idec Limited Innovation House 70 Norden Road Maidenhead
Biogen Idec Limited, Innovation House, 70 Norden Road, Maidenhead, Berkshire, SL6 4AY, United Kingdom.
Biogen Idec Limited, Innovation House, 70 Norden Road, Maidenhead, Berkshire, SL6 4AY, Velika Britanija.
Biogen Inc., 250 Binney Street, Cambridge, Massachusetts 02142, USA.
Biogen Inc., 250 Binney Street, Cambridge, Massachusetts 02142, ZDA
Biogen Inc., 5000 Davis Drive, POB 14627, Research Triangle Park, North Carolina, 27709, USA.
Biogen Inc., 5000 Davis Drive, POB 14627, Research Triangle Park, North Carolina, 27709, ZDA
Biograstim 30 MIU/0.5 mL
Biograstim 30 000 k.i.e./0,5 ml
Biograstim 30 MIU/0.5 mL
Biograstim 30 000 k.i.e./0.5 ml
Biograstim 30 MIU/0.5 mL solution for injection or infusion
Biograstim 30 000 k.i.e./0,5 ml raztopina za injiciranje ali infundiranje
Biograstim 30 MIU/0.5 mL solution for injection or infusion Biograstim 48 MIU/0.8 mL solution for injection or infusion
Biograstim 30 000 k.i.e./0,5 ml raztopina za injiciranje ali infundiranje Biograstim 48 000 k.i.e./0,8 ml raztopina za injiciranje ali infundiranje
Biograstim 48 MIU/0.8 mL
Biograstim 48 000 k.i.e./0,8 ml
Biograstim 48 MIU/0.8 mL solution for injection or infusion
Biograstim 48 000 k.i.e./0,8 ml raztopina za injiciranje ali infundiranje
Biograstim and neutropenia in patients with HIV infection
Zdravilo Biograstim in nevtropenija pri bolnikih, okuženih s HIV
Biograstim and peripheral blood stem cell mobilisation
Zdravilo Biograstim in zbiranje matičnih celic iz periferne krvi
Biograstim and severe chronic neutropenia
Zdravilo Biograstim in huda kronična nevtropenija
Biograstim contains sorbitol and sodium
Zdravilo Biograstim vsebuje sorbitol in natrij
Biograstim is a solution for injection or infusion in a pre-filled syringe with or without safety device.
Zdravilo Biograstim je raztopina za injiciranje ali infundiranje v napolnjeni injekcijski brizgi z varnostnim pripomočkom ali brez njega.
Biograstim is a ‘biosimilar’ medicine.
Zdravilo Biograstim je podobno biološko zdravilo.
Biograstim is useful in several different conditions, which are:
Zdravilo Biograstim pomaga pri več različnih stanjih, med katere spadajo:
Biologic Use
Uporaba biološkega zdravila
Biological effects that may be mediated by Plegridy include up-regulation of anti-inflammatory cytokines (e.g.
Biološki učinki, pri katerih morda posreduje zdravilo Plegridy, vključujejo povišano izražanje protivnetnih citokinov (npr.
Biological response markers (e.g., 2’,5’-OAS activity, neopterin and beta 2-microglobulin) are induced by interferon beta-1a following subcutaneous doses administered to healthy volunteer subjects.
Interferon beta-1a inducira biološke označevalce odziva (npr. aktivnost 2’,5’-OAS, neopterin in beta-2-mikroglobulin) po dajanju subkutanih odmerkov zdravim prostovoljcem.
Biological/ Immunomodulat or
granulocitov
BioMarin Europe Limited 10 Bloomsbury Way London, WC1A 2SL United Kingdom
BioMarin Europe Limited 10 Bloomsbury Way London, WC1A 2SL Velika Britanija